These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 23460348)

  • 1. Effects of a human compact anti-ErbB2 antibody on gastric cancer.
    Fedele C; Carvalho S; Riccio G; Paciello R; Laccetti P; Schmitt F; De Lorenzo C
    Gastric Cancer; 2014 Jan; 17(1):107-15. PubMed ID: 23460348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ErbB2-targeting antibody trastuzumab and the small-molecule SRC inhibitor saracatinib synergistically inhibit ErbB2-overexpressing gastric cancer.
    Han S; Meng Y; Tong Q; Li G; Zhang X; Chen Y; Hu S; Zheng L; Tan W; Li H; Chen Y; Zhang G; Li B; Guo Y
    MAbs; 2014; 6(2):403-8. PubMed ID: 24492292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a human compact anti-ErbB2 antibody on prostate cancer.
    Malara AE; Fedele C; Aloj L; Arra C; Laccetti P; D'Alessio G; De Lorenzo C
    Oncol Rep; 2012 Jul; 28(1):297-302. PubMed ID: 22505344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel fully human antitumour immunoRNase targeting ErbB2-positive tumours.
    Borriello M; Laccetti P; Terrazzano G; D'Alessio G; De Lorenzo C
    Br J Cancer; 2011 May; 104(11):1716-23. PubMed ID: 21559015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent synergistic anti-tumor activity of a novel humanized anti-HER2 antibody hersintuzumab in combination with trastuzumab in xenograft models.
    Shiravi F; Mohammadi M; Golsaz-Shirazi F; Bahadori T; Judaki MA; Fatemi F; Zare HA; Haghighat FN; Mobini M; Jeddi-Tehrani M; Amiri MM; Shokri F
    Invest New Drugs; 2021 Jun; 39(3):697-704. PubMed ID: 33389387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition.
    Raja SM; Desale SS; Mohapatra B; Luan H; Soni K; Zhang J; Storck MA; Feng D; Bielecki TA; Band V; Cohen SM; Bronich TK; Band H
    Oncotarget; 2016 Mar; 7(9):10522-35. PubMed ID: 26859680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining trastuzumab and cetuximab combats trastuzumab-resistant gastric cancer by effective inhibition of EGFR/ErbB2 heterodimerization and signaling.
    Zheng L; Tan W; Zhang J; Yuan D; Yang J; Liu H
    Cancer Immunol Immunother; 2014 Jun; 63(6):581-6. PubMed ID: 24668364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving gastric cancer preclinical studies using diverse in vitro and in vivo model systems.
    Chang HR; Park HS; Ahn YZ; Nam S; Jung HR; Park S; Lee SJ; Balch C; Powis G; Ku JL; Kim YH
    BMC Cancer; 2016 Mar; 16():200. PubMed ID: 26955870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models.
    Shen G; Huang H; Zhang A; Zhao T; Hu S; Cheng L; Liu J; Xiao W; Ling B; Wu Q; Song L; Wei W
    Cancer Immunol Immunother; 2011 Mar; 60(3):339-48. PubMed ID: 21086124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological properties of a human compact anti-ErbB2 antibody.
    De Lorenzo C; Cozzolino R; Carpentieri A; Pucci P; Laccetti P; D'Alessio G
    Carcinogenesis; 2005 Nov; 26(11):1890-5. PubMed ID: 15930029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combinatorial experimental protocols for Erbicin-derived immunoagents and Herceptin.
    De Lorenzo C; Troise F; Cafaro V; D'Alessio G
    Br J Cancer; 2007 Nov; 97(10):1354-60. PubMed ID: 17923870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combating acquired resistance to trastuzumab by an anti-ErbB2 fully human antibody.
    Wang C; Wang L; Yu X; Zhang Y; Meng Y; Wang H; Yang Y; Gao J; Wei H; Zhao J; Lu C; Chen H; Sun Y; Li B
    Oncotarget; 2017 Jun; 8(26):42742-42751. PubMed ID: 28514745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model.
    Yamashita-Kashima Y; Shu S; Harada N; Fujimoto-Ouchi K
    Oncol Rep; 2013 Sep; 30(3):1087-93. PubMed ID: 23783223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models.
    Fujimoto-Ouchi K; Sekiguchi F; Yasuno H; Moriya Y; Mori K; Tanaka Y
    Cancer Chemother Pharmacol; 2007 May; 59(6):795-805. PubMed ID: 17031648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of cardiotoxicity associated with ErbB2 inhibitors.
    Fedele C; Riccio G; Malara AE; D'Alessio G; De Lorenzo C
    Breast Cancer Res Treat; 2012 Jul; 134(2):595-602. PubMed ID: 22674190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours.
    Gelardi T; Damiano V; Rosa R; Bianco R; Cozzolino R; Tortora G; Laccetti P; D'Alessio G; De Lorenzo C
    Br J Cancer; 2010 Feb; 102(3):513-9. PubMed ID: 20051960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2/HER2 homodimers and HER2/EGFR heterodimers internalization leading to potent antitumor activity in HER2-positive human gastric cancer.
    Wei R; Zhang W; Yang F; Li Q; Wang Q; Liu N; Zhu J; Shan Y
    J Transl Med; 2024 Jul; 22(1):641. PubMed ID: 38982548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer.
    Nam HJ; Ching KA; Kan J; Kim HP; Han SW; Im SA; Kim TY; Christensen JG; Oh DY; Bang YJ
    Mol Cancer Ther; 2012 Feb; 11(2):439-51. PubMed ID: 22135232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer.
    Zhu Y; Tian T; Zou J; Wang Q; Li Z; Li Y; Liu X; Dong B; Li N; Gao J; Shen L
    BMC Cancer; 2015 Nov; 15():894. PubMed ID: 26560145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models.
    Kuo WY; Hsu HJ; Wu CY; Chen HS; Chou YC; Tsou YL; Peng HP; Jian JW; Yu CM; Chiu YK; Chen IC; Tung CP; Hsiao M; Lin CL; Wang YA; Wang AH; Yang AS
    MAbs; 2019 Jan; 11(1):153-165. PubMed ID: 30365359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.